Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Up 1.2 %

Shares of Titan Pharmaceuticals stock opened at $6.82 on Thursday. The company has a fifty day simple moving average of $7.19 and a 200-day simple moving average of $7.02. Titan Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $16.60. The stock has a market cap of $6.23 million, a price-to-earnings ratio of -0.83 and a beta of 1.32.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.